ArticleCell genomics2025
SpaLinker identifies phenotype-associated spatial tumor microenvironment features by integrating bulk and spatial sequencing data.
Article in Cell genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- SpaPheno: linking spatial transcriptomics to clinical phenotypes with interpretable machine learning.Genome medicine · 2026Article
- Spatial niches of the colorectal cancer microbiome: differences, interrelationships, and clinical implications of fecal, mucosal, and intratumoral microbiota.Frontiers in cellular and infection microbiology · 2026Review
- Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions.Molecular cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of spatial transcriptomics (ST) technology offers unprecedented opportunities to elucidate the complexity and heterogeneity of the tumor microenvironment (TME). However, quantitatively linking spatially resolved features with clinical phenotypes remains challenging due to the scarcity of clinical annotations of spatial sequencing samples. Herein, we introduce SpaLinker, an innovative integrated framework that utilizes ST data to decipher spatially resolved TMEs at molecular, cellular, and tissue structure levels. Specifically, it assesses the prognostic significance of spatially defined features by integrating well-accumulated bulk RNA sequencing (RNA-seq) data, using a phenotype-driven computational framework. Applying SpaLinker to diverse tumor ST datasets demonstrated its utility and effectiveness in recognizing spatial architectures, including tertiary lymphoid structures and tumor-normal interfaces, and in establishing links to distinct clinical outcomes. Overall, this study presents a valuable and comprehensive pan-cancer analytical platform to de novo identify phenotype-associated spatial TME features, significantly enhancing the clinical utility of spatial sequencing technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.